BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 24952028)

  • 1. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.
    Ugras S; Stempel M; Patil S; Morrow M
    Ann Surg Oncol; 2014 Nov; 21(12):3780-6. PubMed ID: 24952028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.
    Pilewskie M; Zabor EC; Mamtani A; Barrio AV; Stempel M; Morrow M
    Ann Surg Oncol; 2017 Nov; 24(12):3527-3533. PubMed ID: 28762114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presenting features of breast cancer differ by molecular subtype.
    Wiechmann L; Sampson M; Stempel M; Jacks LM; Patil SM; King T; Morrow M
    Ann Surg Oncol; 2009 Oct; 16(10):2705-10. PubMed ID: 19593632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
    Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
    Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status.
    Freedman GM; Fowble BL; Li T; Hwang ES; Schechter N; Devarajan K; Anderson PR; Sigurdson ER; Goldstein LJ; Bleicher RJ
    Breast J; 2014; 20(4):358-63. PubMed ID: 24861613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery.
    Chung A; Gangi A; Mirocha J; Giuliano A
    Ann Surg Oncol; 2015 Apr; 22(4):1128-32. PubMed ID: 25300606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
    Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
    Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
    Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
    Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?
    Pilewskie M; Mautner SK; Stempel M; Eaton A; Morrow M
    Ann Surg Oncol; 2016 Apr; 23(4):1123-8. PubMed ID: 26553439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Neoadjuvant Versus Adjuvant Chemotherapy on the Extent of Axillary Surgery for Clinically Node-Negative Breast Cancers of Triple-Negative and HER2-Overexpressing Phenotypes.
    Thompson JL; Wrubel E; Davis AT; Koehler T; Chung MH; Wright GP
    Clin Breast Cancer; 2020 Oct; 20(5):390-394. PubMed ID: 32444317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected features of breast cancer subtype.
    Liu YH; Wang OC; Chen ED; Cai YF; Pan CM; Yang F; Zhang XH
    World J Surg Oncol; 2015 Aug; 13():249. PubMed ID: 26271634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Neoadjuvant Chemotherapy on Nodal Disease and Nodal Surgery by Tumor Subtype.
    Al-Hilli Z; Hoskin TL; Day CN; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Feb; 25(2):482-493. PubMed ID: 29181679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis.
    Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W
    Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Subtype is Associated With Axillary Lymph Node Metastasis: A Retrospective Cohort Study.
    He ZY; Wu SG; Yang Q; Sun JY; Li FY; Lin Q; Lin HX
    Medicine (Baltimore); 2015 Dec; 94(48):e2213. PubMed ID: 26632910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.